Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
Public ClinicalTrials.gov record NCT03452332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Study identification
- NCT ID
- NCT03452332
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Advanced Cervical Adenocarcinoma
- Advanced Vaginal Carcinoma
- Advanced Vulvar Carcinoma
- Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
- Metastatic Cervical Adenocarcinoma
- Metastatic Cervical Carcinoma
- Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Metastatic Vaginal Adenocarcinoma
- Metastatic Vaginal Carcinoma
- Metastatic Vulvar Carcinoma
- Recurrent Cervical Adenocarcinoma
- Recurrent Cervical Carcinoma
- Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Vaginal Carcinoma
- Recurrent Vulvar Carcinoma
- Stage III Cervical Cancer AJCC v8
- Stage III Vaginal Cancer AJCC v8
- Stage III Vulvar Cancer AJCC v8
- Stage IIIA Cervical Cancer AJCC v8
- Stage IIIA Vulvar Cancer AJCC v8
- Stage IIIB Cervical Cancer AJCC v8
- Stage IIIB Vulvar Cancer AJCC v8
- Stage IIIC Vulvar Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Vaginal Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Vaginal Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Vulvar Adenocarcinoma
- Vulvar Squamous Cell Carcinoma
Interventions
- Durvalumab Biological
- Laboratory Biomarker Analysis Other
- Stereotactic Radiosurgery Radiation
- Tremelimumab Biological
Biological · Other · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2018
- Primary completion
- Aug 10, 2023
- Completion
- Aug 10, 2023
- Last update posted
- Sep 12, 2023
2018 – 2023
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | 75390 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03452332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 12, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03452332 live on ClinicalTrials.gov.